Tessa Romero
Stock Analyst at JP Morgan
(4.44)
# 316
Out of 5,149 analysts
77
Total ratings
55.93%
Success rate
21.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Neutral | $17 → $16 | $16.15 | -0.93% | 8 | Jan 20, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $70 → $74 | $61.43 | +20.46% | 6 | Jan 20, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $60 → $62 | $42.55 | +45.71% | 4 | Jan 9, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $20 → $25 | $29.20 | -14.38% | 8 | Jan 6, 2026 | |
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $28.61 | +32.82% | 1 | Dec 19, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $11.81 | +27.01% | 8 | Nov 20, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $46 → $47 | $43.48 | +8.10% | 6 | Nov 18, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $4.97 | +5,191.75% | 1 | Nov 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $33 → $31 | $22.81 | +35.91% | 11 | Nov 17, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $33 → $34 | $29.70 | +14.48% | 11 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.20 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $7.13 | +40.25% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $7.70 | +393.51% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.96 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $18.34 | +58.12% | 3 | Aug 13, 2024 |
Dyne Therapeutics
Jan 20, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $16.15
Upside: -0.93%
Cytokinetics
Jan 20, 2026
Maintains: Overweight
Price Target: $70 → $74
Current: $61.43
Upside: +20.46%
Xenon Pharmaceuticals
Jan 9, 2026
Maintains: Overweight
Price Target: $60 → $62
Current: $42.55
Upside: +45.71%
Agios Pharmaceuticals
Jan 6, 2026
Maintains: Neutral
Price Target: $20 → $25
Current: $29.20
Upside: -14.38%
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $28.61
Upside: +32.82%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $11.81
Upside: +27.01%
Scholar Rock Holding
Nov 18, 2025
Maintains: Overweight
Price Target: $46 → $47
Current: $43.48
Upside: +8.10%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $4.97
Upside: +5,191.75%
ACADIA Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $33 → $31
Current: $22.81
Upside: +35.91%
Edgewise Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $29.70
Upside: +14.48%
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $3.20
Upside: -
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $7.13
Upside: +40.25%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $7.70
Upside: +393.51%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $8.96
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $18.34
Upside: +58.12%